Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

Pharmerica Corporation (PMC)

(Delayed Data from NYSE)

$29.25 USD

+0.05 (0.17%)

Updated Dec 7, 2017 04:02 PM ET

29.25-Market: $29.25 (%) 6:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[PMC]

Reports for Purchase

Showing records 1 - 20 ( 71 total )

Industry: Medical - Outpatient and Home Healthcare

Record: 1

12/07/2017

Pages: 4

Terminating Coverage

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 2

08/02/2017

Pages: 5

We are downgrading shares to SW

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 3

08/02/2017

Pages: 8

Research Summary

Provider: KEYBANC CAPITAL MARKETS

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 4

05/15/2017

Pages: 5

Raising Estimates Slightly on Solid 1Q

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 5

05/15/2017

Pages: 12

Research Summary

Provider: KEYBANC CAPITAL MARKETS

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 6

04/07/2017

Pages: 8

Morning Meeting Notes

Provider: KEYBANC CAPITAL MARKETS

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 7

04/06/2017

Pages: 5

Value Opportunity as Rate Cut Overshadows Business Mix Improvement

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 8

02/26/2017

Pages: 7

Can?t Catch a Break, but Diversified Growth Does Look Promising

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 9

02/24/2017

Pages: 5

4Q16 Conference Call Notes

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 10

02/24/2017

Pages: 3

2017 Outlook Disappoints Despite Strong 4Q

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 11

12/04/2016

Industry Report

Pages: 11

Healthcare Facilities and Services: ACA Repeal and Replace - Lots of Noise, but Risks Appear Modest

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 12

11/09/2016

Pages: 5

3Q16 Conference Call Notes

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 13

11/09/2016

Pages: 3

3Q Miss - Guidance Reduced on LTC Weakness

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 14

11/09/2016

Pages: 7

Encouraging 2017 Outlook Despite Recent Weakness

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 15

08/25/2016

Pages: 6

We Believe There Is a Good Chance PMC Will Find a Buyer

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 16

08/09/2016

Pages: 5

2Q16 Conference Call Notes

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 17

08/09/2016

Pages: 3

In-Line 2Q, as Strong Specialty Growth/Diversification Continues

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 18

08/09/2016

Pages: 7

Modest LTC Headwind Does Not Detract from LT Value Proposition

Provider: KEYBANC CAPITAL MARKETS

Analyst: GURDA J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 19

08/09/2016

Pages: 17

Research Summary

Provider: KEYBANC CAPITAL MARKETS

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Outpatient and Home Healthcare

Record: 20

07/21/2016

Pages: 15

Morning Meeting Notes

Provider: KEYBANC CAPITAL MARKETS

Price: 50.00

Research Provided by a Third Party

previous
1
2
3
4
next

// eof